989 related articles for article (PubMed ID: 19328973)
1. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
[TBL] [Abstract][Full Text] [Related]
2. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
3. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
[TBL] [Abstract][Full Text] [Related]
4. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
Cataneo-Dávila A; Zúñiga-Varga J; Correa-Rotter R; Alberú J
Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
[TBL] [Abstract][Full Text] [Related]
5. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
6. Protocol conversion from a calcineurin inhibitor based therapy to sirolimus.
Oberbauer R
Transplantation; 2009 Apr; 87(8 Suppl):S7-10. PubMed ID: 19384186
[TBL] [Abstract][Full Text] [Related]
7. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
[TBL] [Abstract][Full Text] [Related]
9. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
[TBL] [Abstract][Full Text] [Related]
10. Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: a prospective, protocol biopsy-guided study.
Pankewycz O; Leca N; Kohli R; Weber-Shrikant E; Said M; Alnimri M; Feng L; Patel S; Laftavi MR
Transplant Proc; 2011 Mar; 43(2):519-23. PubMed ID: 21440749
[TBL] [Abstract][Full Text] [Related]
11. Improved 24-hour blood pressure control with sirolimus versus calcineurin inhibitor based immunosuppression in renal transplant recipients.
Steigerwalt SP; Brar N; Dhungel A; Butcher D; Steigerwalt S; El-Ghouroury M; Provenzano R
Transplant Proc; 2009 Dec; 41(10):4184-7. PubMed ID: 20005365
[TBL] [Abstract][Full Text] [Related]
12. Conversion from calcineurin inhibitors to sirolimus in kidney transplant recipients: a retrospective cohort study.
Cardinal H; Froidure A; Dandavino R; Daloze P; Hébert MJ; Colette S; Boucher A
Transplant Proc; 2009 Oct; 41(8):3308-10. PubMed ID: 19857737
[TBL] [Abstract][Full Text] [Related]
13. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
[TBL] [Abstract][Full Text] [Related]
14. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C
Pediatr Transplant; 2006 Jun; 10(4):474-8. PubMed ID: 16712606
[TBL] [Abstract][Full Text] [Related]
15. Five-year follow-up after late conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction.
Krüger B; Fischereder M; Jauch KW; Graeb C; Hoffmann U; Böger CA; Banas B; Obed A; Schlitt HJ; Krämer BK
Transplant Proc; 2007 Mar; 39(2):518-21. PubMed ID: 17362772
[TBL] [Abstract][Full Text] [Related]
16. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation.
Stephany BR; Augustine JJ; Krishnamurthi V; Goldfarb DA; Flechner SM; Braun WE; Hricik DE; Dennis VW; Poggio ED
Transplantation; 2006 Aug; 82(3):368-74. PubMed ID: 16906035
[TBL] [Abstract][Full Text] [Related]
17. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
18. Early sirolimus therapy in renal transplant recipients at high risk: is it justified?
Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Al-Waheeb S; Hasaneen H; Awadain WH; Nawas KM; El-Sayed A; Said T; Nair MP; Nampoory MR
Transplant Proc; 2009 Sep; 41(7):2784-8. PubMed ID: 19765435
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
[TBL] [Abstract][Full Text] [Related]
20. Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure.
Carmellini M; Collini A; Ruggieri G; Garosi G; Bernini M
Transplant Proc; 2008; 40(6):1858-61. PubMed ID: 18675070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
